Search

Displaying results 6391 - 6400 of 8171 in total
  1. Drug

    Minzasolmin

    go.drugbank.com/drugs/DB18961
    Investigational

    Minzasolmin is under investigation in clinical trial NCT05543252 (An Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's

  2. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  3. Drug

    9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide

    go.drugbank.com/drugs/DB02842
    Experimental

    9-amino-n-[3-(dimethylamino)propyl]acridine-4-carboxamide is an inactive derivative of the antitumour agents N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 9-amino-DACA.

  4. Drug

    AAV8-RK-RetGC

    go.drugbank.com/drugs/DB32389
    Experimental

    AAV8-RK-RetGC is an adeno-associated virus (AAV) viral vector platform with a serotype 8 capsid with a complementary DNA (cDNA) of the human GUCY2D gene encoding RetGC.

  5. Drug

    Ciluprevir

    go.drugbank.com/drugs/DB05868
    Investigational

    The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

  6. Drug

    Nemiralisib

    go.drugbank.com/drugs/DB16253
    Investigational

    Nemiralisib is under investigation in clinical trial NCT03345407 (Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary

  7. Drug

    Corticosterone

    go.drugbank.com/drugs/DB04652
    Investigational

    An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Inhibitors
  9. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine has a monoisotopic molecular weight of 691.29 Da.

  10. Drug

    Neutramycin

    go.drugbank.com/drugs/DB20809
    Experimental

    Neutramycin has a monoisotopic molecular weight of 686.35 Da.